

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



TYK Medicines, Inc

浙江同源康醫藥股份有限公司

*(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2410)*

VOLUNTARY ANNOUNCEMENT

THE COMPANY HAS BEEN GRANTED THE DRUG MANUFACTURING LICENSE BY THE DRUG ADMINISTRATION OF ZHEJIANG PROVINCE

This announcement is made by TYK Medicines, Inc (浙江同源康醫藥股份有限公司) (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business developments of the Group.

The board of directors (the “**Board**”) of the Company is pleased to announce that the Company has been granted the Drug Manufacturing License (“**DML**”) by the Drug Administration of Zhejiang Province. Details of the DML are as follows:

I. MAJOR INFORMATION OF THE DML

The name of the Company: TNK Medicines, Inc.

Registered address: Room 1403-2, 14th Floor, Tower A, Changxing World Trade Building, No. 1278 Mingzhu Road, Changxing Economic Development Zone, Huzhou, Zhejiang Province

Production address and production range: trustee manufacturer: Asymchem Life Science (Tianjin) Co., Ltd. at No.71, 7th Street, Economic-Technological Development Area, Tianjin, TY-9591***

License number: Zhejiang 20260002

Valid until: January 22, 2031

Issuing authority: Drug Administration of Zhejiang Province

II. EFFECT ON THE COMPANY

This obtainment of the DML is expected to have a long-term positive impact on the Company's capacity expansion and market expansion, which lays the foundation for subsequent commercial production, enabling us to provide better treatment options for patients sooner to address unmet medical needs in cancer treatment.

Warning under Rule 18A.05 of the Listing Rules: There is no assurance that the relevant product will ultimately be successfully developed and marketed by the Company. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
TYK Medicines, Inc
(浙江同源康醫藥股份有限公司)
Dr. WU Yusheng
*Chairman, Executive Director and
Chief Executive Officer*

Hong Kong, 23 January, 2026

As at the date of this announcement, the Board comprises Dr. WU Yusheng as executive Director, Dr. LI Jun, Dr. GU Eric Hong, Dr. JIANG Mingyu, Mr. HE Chao and Dr. ZHU Xiangyang as non-executive Directors, and Dr. LENG Yuting, Dr. XU Wenqing, Dr. SHEN Xiuhua and Mr. JIANG Xiaolin as independent non-executive Directors.